More program cuts ahead as Sanofi CEO Paul Hudson continues to reshape the company
One quarter into the new year, Sanofi CEO Paul Hudson remains steadfast on his mission to reshape the company — and that will mean some serious pipeline pruning, particularly in the general medicines unit.
In late 2019 and early 2020, Sanofi’s general medicines unit boasted more than 350 product families, according to Olivier Charmeil, EVP of general medicines. By the end of this year, the company aims to reduce that figure to about 125, either by divesting or discontinuing programs. And by 2025, the goal is to sit at right around 100 product families.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
